Benzinga · Jul 17, 2026
Tvardi Therapeutics Increases At-The-Market Offering Program To $9.69M In Shares
- Sec Filing
TV
NASDAQ · TVRD
Tvardi Therapeutics, Inc.
Healthcare · Biotechnology
$1.73
Down-$0.11 (-6.36%)
Updated Sep 17, 2026, 10:00 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 42.12M
- P/E ratio
- -3.02
- Dividend yield
- 0.00%
- 52-week range
- $1.50 – $43.65
- Volume
- 126.68K
- Avg. volume
- 308.7K
Price performance
TVRD price history
1M range · 20 trading sessions · Daily adjusted prices
TVRD closed at $1.73 after 20 trading sessions, down 7.98% for the selected period.
- Last close
- $1.73
- Period change
- -7.98%
- Period low
- $1.73
- Period high
- $1.94
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $1.74 | $1.805 | $1.73 | $1.73 | 126.68K |
| Sep 15, 2026 | $1.83 | $1.836 | $1.735 | $1.76 | 115.66K |
| Sep 14, 2026 | $1.89 | $2.00 | $1.81 | $1.83 | 174.15K |
| Sep 11, 2026 | $1.83 | $1.94 | $1.83 | $1.87 | 116.44K |
| Sep 10, 2026 | $1.83 | $1.90 | $1.81 | $1.835 | 77.5K |
| Sep 9, 2026 | $1.92 | $1.94 | $1.85 | $1.85 | 97.11K |
| Sep 8, 2026 | $1.91 | $1.9586 | $1.87 | $1.94 | 164.23K |
| Sep 4, 2026 | $1.85 | $1.92 | $1.81 | $1.91 | 73.28K |
| Sep 3, 2026 | $1.89 | $1.91 | $1.84 | $1.85 | 98.76K |
| Sep 2, 2026 | $1.75 | $1.88 | $1.75 | $1.88 | 107.89K |
| Sep 1, 2026 | $1.81 | $1.84 | $1.745 | $1.745 | 96.83K |
| Aug 31, 2026 | $1.82 | $1.84 | $1.755 | $1.80 | 118.58K |
| Aug 28, 2026 | $1.80 | $1.9188 | $1.78 | $1.82 | 338.76K |
| Aug 27, 2026 | $1.79 | $1.84 | $1.78 | $1.80 | 70.97K |
| Aug 26, 2026 | $1.82 | $1.83 | $1.76 | $1.78 | 87.5K |
| Aug 25, 2026 | $1.79 | $1.89 | $1.785 | $1.82 | 77.06K |
| Aug 24, 2026 | $1.87 | $1.87 | $1.77 | $1.78 | 63.36K |
| Aug 21, 2026 | $1.83 | $1.9295 | $1.82 | $1.86 | 166.83K |
| Aug 20, 2026 | $1.87 | $1.89 | $1.82 | $1.83 | 126.17K |
| Aug 19, 2026 | $1.99 | $2.0072 | $1.85 | $1.88 | 201.94K |
Latest TVRD news
The latest Smart Investors Daily articles mentioning TVRD.
Stock researchCompany · Overview
TVRD research
Overview
Company profile and research snapshot.
Company profile
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $4.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | BTIG | Buy | — |
| Jul 8, 2026 | Raymond James | Outperform | — |
| Jul 7, 2026 | BTIG | Buy | — |
| Jun 8, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 20, 2026 | Barclays | Underweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 9, 2026
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences (NASDAQ:FBRX) stock rose
Benzinga · Jul 9, 2026
Why Is Tvardi Therapeutics Stock Falling Thursday?
Tvardi Therapeutics stock dips premarket as investors take profits after positive Phase 1 data for Tvardi's STAT3 prodrug TTI-109.
Benzinga · Jul 9, 2026
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals (NASDAQ:ALNY) stock
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
